Cancer Therapy in Clinical Practice Session 2a - Side Effects of Targeted Therapy

Cancer Therapy in Clinical Practice Session 2a - Side Effects of Targeted Therapy

Cancer Therapy in Clinical Practice Session 2a - Side Effects of Targeted Therapy (6401)

Dan Mellor ¹

Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Targeted therapies are becoming more common in the fight against cancer. They are used in both haematological and solid malignancies and do not cause many of the generalised side effects common to conventional chemotherapy. However, they are not free from side effects. This presentation will deliver an overview of common toxicities associated with targeted and biological anticancer agents and their management with an emphasis on the management of skin toxicities.

Authors contributing to this presentation.

Mellor, D

Dan Mellor is the Deputy Director of Pharmacy at Peter Mac. He is currently completing a PhD in Cancer Pharmacogenomics and also holds a post-graduate qualification in clinical oncology research. Dan is Chair of the COSA Cancer Pharmacists Group and a member of the COSA Council. Dan is frequently invited to speak at national and international conferences. He is an active researcher authoring 11 peer-reviewed publications and 25 conference abstracts. Dan’s achievements have been recognized by the SHPA when he became the 2012 recipient of the William Mercer Young Achiever’s Award recognising an outstanding contribution to hospital pharmacy.

Cancer Therapy in Clinical Practice Session 2a - Side Effects of Targeted Therapy (6401)

Add notes

Mellor, D

Login